NEW YORK, June 26, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Agile Therapeutics, Inc. (NASDAQ: AGRX), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Galena Biopharma, Inc. (NASDAQ: GALE), Nanosphere, Inc. (NASDAQ: NSPH) and Rockwell Medical Technologies Inc. (NASDAQ: RMTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4128-100free.
--
Agile Therapeutics, Inc. Analyst Notes
On June 20, 2014, Agile Therapeutics, Inc. (Agile) announced the issuance of the patent U.S. 8,747,888 ('888 Patent) for the Company's Skinfusion Transdermal Delivery Device by the U.S. Patent and Trademark Office. The Company informed that the patent is a continuation of its prior patent US 8,246,978 and aims to provide additional patent protection covering its contraceptive patch, Twirla™ ethinyl estradiol and levonorgestrel transdermal system. "The granting of this patent further strengthens the patent protection of our proprietary Skinfusion® transdermal technology used in our contraceptive patch, Twirla currently in Phase 3 clinical development," said Al Altomari, CEO and President of Agile. "The issuance of this patent demonstrates our commitment to protecting our intellectual property in our proprietary transdermal technology and is expected to provide protection into 2028." The full analyst notes on Agile Therapeutics are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/AGRX/report.pdf
--
Vanda Pharmaceuticals, Inc. Analyst Notes
On June 23, 2014, Vanda Pharmaceuticals Inc.'s (Vanda) stock increased 7.78% to end the day at $15.93, compared to the previous day's closing price of $14.78. The Company's stock has grown 8.22% over the past three trading days, significantly outperforming the broader market indices. For instance, the Nasdaq Composite gained 0.13%, while the Dow Jones Industrial Average increased 0.18% over the same period of time. The full analyst notes on Vanda are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/VNDA/report.pdf
--
Galena Biopharma, Inc. Analyst Notes
On June 17, 2014, Galena Biopharma, Inc.'s (Galena) announced that it has completed the patient enrollment of the Company's Phase 2a clinical trial for GALE-301, or Folate Binding Protein (FBP) peptide immunotherapy. GALE-301 is administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant treatment to prevent recurrences in high-risk, ovarian and endometrial cancer patients rendered disease-free after completing standard of care therapy. "Completion of enrollment in the GALE-301 Phase 2a clinical trial ahead of schedule is an important milestone for Galena," said Mark J. Ahn, Ph.D., President and CEO of Galena. "We are now in the treatment and follow-up phase of the trial with the expectation of data readout in mid-2015. With promising results from the Phase 1 trial, we are encouraged to advance the GALE-301 program forward to prevent recurrence in women suffering from gynecological cancers." The full analyst notes on Galena are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/GALE/report.pdf
--
Nanosphere, Inc. Analyst Notes
On June 23, 2014, Nanosphere, Inc. (Nanosphere) announced that HealthTrust has selected the Company to provide multi-target molecular diagnostic tests for the nearly 1,400 acute care facilities that are part of the HealthTrust membership. Under the terms of agreement, HealthTrust will offer its members access to purchase Nanosphere's portfolio of Verigene® multiplex molecular diagnostic infectious disease tests, including those designed to rapidly and accurately detect infections of the bloodstream, respiratory tract and gastrointestinal tract. The full analyst notes on Nanosphere are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/NSPH/report.pdf
--
Rockwell Medical Technologies Inc. Analyst Notes
On June 23, 2014, Rockwell Medical, Inc. (Rockwell) announced the FDA approval of the Company's Supplemental Abbreviated New Drug Application (sANDA) to manufacture Calcitriol - the Company's low-cost generic active vitamin D drug. "Achieving this FDA approval is a significant achievement for Rockwell and it enables us to execute on our strategic initiative to begin selling Calcitriol in the renal market, where the CMS bundled-reimbursement payment system has incentivized dialysis service providers to utilize the lowest cost drugs," stated Mr. Robert L. Chioini, Founder, Chairman and CEO of Rockwell. "We believe Rockwell is uniquely positioned to generate dynamic sales growth by offering the dialysis market the original, low-cost generic vitamin D injection in vials. We are targeting commercial launch for year end." The full analyst notes on Rockwell are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/RMTI/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
